Protein That Protects Against Alzheimer’s Disease Identified

VGF protein plays a key role in protecting the brain against Alzheimer’s disease, according to results from a large study conducted by scientists from the Icahn School of Medicine at Mount Sinai, Emory University, and collaborating institutions. The paper was published in Nature Communications. Despite intensive research, the molecular underpinnings of Alzheimer’s disease have not yet been fully characterized. Genome-wide association studies have implicated more than two dozen genetic regions associated with disease risk, but this information has proven difficult to translate into clinical use.

In this study, scientists built predictive network models of late-onset Alzheimer’s disease by mining DNA, RNA, protein, and clinical data. These models allowed them to identify key regulators of the disease and spotlighted VGF, the only key driver of a suppressed response across all datasets. VGF is a neuronal protein that regulates memory; levels of it are reduced in the brains and cerebrospinal fluid of patients with Alzheimer’s disease.

“Our results support previous studies in demonstrating that the biology of Alzheimer’s disease is highly complex, and that there is no single genetic cause of the disease,” said Noam Beckmann, PhD, a postdoctoral fellow at the Icahn School of Medicine at Mount Sinai and a lead author of the paper.

“However, our sophisticated model and follow-up validation studies offer convincing evidence that the protein VGF, previously associated with fear and spatial memories in mice, plays an important role in protecting the brain against the onset and progression of Alzheimer’s disease.”

While lower levels of VGF had been noted in previous Alzheimer’s disease studies, this is the first time that reduced levels of the protein have been shown to have a causal role in the disease. Scientists replicated the VGF findings in other datasets, and then used multiple mouse models to study overexpression of VGF.

By dialing up levels of the gene or protein in mice, scientists were able to significantly reduce pathogenesis and progression of Alzheimer’s disease, with clear molecular and behavioral effects.

“Our combined big data analysis of gene expression in patients with Alzheimer’s disease and validation studies carried out in mouse models provide novel insights into disease mechanisms,” said Stephen R. J. Salton, MD, PhD, Professor of Neuroscience, and Geriatrics, at the Icahn School of Medicine at Mount Sinai.

“These studies have identified molecular networks and new gene products including VGF that impact Alzheimer’s disease, for future pharmacotherapeutic manipulation, which we anticipate will lead to a reduction in the pathogenesis and progression of this and potentially other neurodegenerative diseases.”

This work was supported by the National Institutes of Health, the National Institute on Aging, the BrightFocus Foundation, the Alzheimer’s Drug Discovery Foundation, the Cure Alzheimer’s Fund, the National Cancer Institute Clinical Proteomic Tumor Analysis Consortium, the Guangdong Science and Technology Department, and the National Natural Science Foundation of China.



Source-Newswise